|Bid||125.65 x 1400|
|Ask||125.92 x 900|
|Day's range||125.28 - 130.30|
|52-week range||120.02 - 236.17|
|Beta (3Y Monthly)||2.25|
|PE ratio (TTM)||N/A|
|Earnings date||30 Oct 2018 - 5 Nov 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||207.81|
LentiGlobin was previously granted an accelerated assessment by the Committee for Medicinal Products for Human Use (CHMP) of the EMA in July 2018, potentially reducing the EMA’s active review time of the MAA from 210 days to 150 days. “People living with transfusion-dependent β-thalassemia require frequent blood transfusions that are life-saving but may lead to complications, including organ failure due to iron overload,” said David Davidson, M.D., chief medical officer, bluebird bio.
bluebird bio, Inc. (BLUE) today announced that members of the management team will present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology, Wednesday, October 3, at 3:30 p.m. ET at the Lotte New York Palace, New York City. To access the live webcast of bluebird bio’s presentation, please visit the “Events & Presentations” page within the Investors and Media section of the bluebird bio website at http://investor.bluebirdbio.com. A replay of the webcast will be available on the bluebird bio website for 90 days following the conferences.
As discussed earlier, Sage Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders. The products under development include SAGE-718 and SAGE-904.
Regenxbio (RGNX) generated revenues, chiefly from licensing, of $40.03 million in the second quarter compared to $6.56 million in Q2 2017. For fiscal 2018, Regenxbio is expected to generate revenues of $194.55 million compared to $10.39 million in fiscal 2017. The increase in revenues helped Regenxbio generate a net income of $10.59 million in the second quarter compared to a net loss of $14.47 million in the second quarter of 2017.
In August, the National Institutes of Health’s (or NIH) recombinant DNA advisory committee completed the NIH protocol for Editas Medicine’s (EDIT) EDIT-101. EDIT-101 is an investigational CRISPR genome editing therapy for the treatment of individuals with LCA10 (Leber Congenital Amaurosis type 10). Editas Medicine plans to submit an IND (Investigational New Drug) application to the FDA in October.
Wall Street analysts estimate that Bluebird Bio (BLUE) will report a 14.6% growth in revenues to ~$40.6 million in 2018 compared to $35.4 million in 2017. Its EPS is expected to be -$10.83 in 2018. Analysts estimate net adjusted loss of $556.6 million in 2018.
Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating the investigational Lenti-D gene therapy for the treatment of cerebral adrenoleukodystrophy (or CALD) in boys aged 17 years or less. The Phase 2/3 Starbeam study met its enrollment goal with the data reported by Bluebird Bio as of April 25. Thirty-one patients were studied, and 29 of them received Lenti-D gene therapy.
Bluebird Bio (BLUE) is a clinical stage biotechnology company. It reported a net loss of $2.91 per share on revenues of $7.8 million in Q2 2018, a 53% decline YoY (year-over-year) compared to $16.72 million in the second quarter of 2017.
On September 4, the European Commission approved the marketing authorization of Puma Biotechnology’s Nerlynx as extended adjuvant therapy for the treatment of adults with early-stage HER2-positive (hormone receptor-2 positive) breast cancer who completed previous adjuvant trastuzumab-containing therapy less than a year ago.
bluebird bio has also reached general agreement with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on the clinical development program to support future marketing applications for Lenti-D in CALD. “Cerebral adrenoleukodystrophy is a genetic disease primarily affecting young boys that causes progressive damage to the brain, leading to the permanent loss of physical and cognitive function, and it is often fatal,” said David Davidson, M.D., chief medical officer, bluebird bio.
To access the live webcasts of bluebird bio’s presentations, please visit the “Events & Presentations” page within the Investors and Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcasts will be available on the bluebird bio website for 90 days following the conferences. With its lentiviral-based gene therapies, T cell immunotherapy expertise and gene editing capabilities, bluebird bio has built a pipeline with broad potential application in severe genetic diseases and cancer.
bluebird bio, Inc. (BLUE) and Gritstone Oncology, Inc. today announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy. Gritstone Oncology will leverage its proprietary EDGE™ artificial intelligence platform to analyze specific tumor types to identify tumor-specific targets and natural T-cell receptors (TCRs) directed to those targets for use in bluebird bio’s established cell therapy platforms.
NovoCure’s (NVCR) net financial expenses increased from $2.18 million in the second quarter of 2017 to $2.86 million in the second quarter. NovoCure’s income tax expenses also increased from $3.46 million in the second quarter of 2017 to $5.56 million in the second quarter.
Editas Medicine (EDIT) is a research-stage genome editing company. Editas makes use of clustered, regularly interspaced, short palindromic repeats (or CRISPR) technology and has developed a proprietary genome editing platform based on it with a product development strategy to chiefly target genetically defined diseases.
The last leg of Q2 earnings in the biotech sector saw Regeneron firing all cylinders. The company also collaborated with bluebird bio, which impressed investors.
BeiGene (BGNE) is a clinical-stage biopharmaceutical company that develops molecularly targeted and immuno-oncology drugs for cancer. BeiGene also markets the drugs Abraxane, Revlimid, and Vidaza in China under its licensing agreement with Celgene (CELG).
Regeneron Pharmaceuticals is investing $100 million in Bluebird Bio in an immuno-oncology collaboration that could rival the likes of Novartis and Gilead Sciences.
Stock futures opened in the red Monday, as chip stocks were active on analyst actions and Bluebird Bio surged on a development deal.
In July 2018, the FDA approved AbbVie’s (ABBV) and Neurocrine Biosciences’ (NBIX) Orilissa for the treatment of women with moderate to severe endometriosis. Orlissa (elagolix) is the first and only GnRH (gonadotropin-releasing hormone) antagonist approved for the treatment of moderate-to-severe endometriosis pain in women.
Neurocrine Biosciences (NBIX) generated revenues of $96.9 million in the second quarter of 2018 compared to $6.3 billion in the second quarter of 2017. In the second quarter of 2018, Neurocrine Biosciences witnessed ~36% growth sequentially. In the first half of 2018, Neurocrine Biosciences generated revenues of $168.0 million.